Takahiro Maeda

Takahiro Maeda

Auto-generated profile, based on publicly available information

Takahiro Maeda

Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2015 in Nature
Verified
Journal Article
Open access
PDF file
MCMatthew C. Canver
Matthew C. Canver
ESElenoe C. Smith
Elenoe C. Smith
FSFalak Sher
Falak Sher
LPLuca Pinello
Luca Pinello
NSNeville E. Sanjana
Neville E. Sanjana
DBDaniel E. Bauer
Daniel E. Bauer
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.

25 May 2015 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
ZZZhen Zhao
Zhen Zhao
ASAbhay P Sagare
Abhay P Sagare
QMQingyi Ma
Qingyi Ma
MHMatthew R Halliday
Matthew R Halliday
PKPan Kong
Pan Kong
BZBerislav V Zlokovic
Berislav V Zlokovic
Zhao et al. report that brain vessels have a major role in clearing Alzheimer's disease–related toxin Aβ from brain and show that PICALM gene product and its variant associated with an increased risk for Alzheimer's disease inactivate an Aβ clearance system in blood vessels, leading to Aβ brain accumulation and cognitive impairment. PICALM is a highly validated genetic risk factor for Alzheimer's disease (AD). We found that reduced expression of PICALM in AD and murine brain endothelium correlated with amyloid-β (Aβ) pathology and cognitive impairment. Moreover, Picalm deficiency diminished Aβ clearance across the murine blood-brain barrier (BBB) and accelerated Aβ pathology in a manner that was reversible by endothelial PICALM re-expression. Using human brain endothelial monolayers, we found that PICALM regulated PICALM/clathrin-dependent internalization of Aβ bound to the low density lipoprotein receptor related protein-1, a key Aβ clearance receptor, and guided Aβ trafficking to Rab5 and Rab11, leading to Aβ endothelial transcytosis and clearance. PICALM levels and Aβ clearance were reduced in AD-derived endothelial monolayers, which was reversible by adenoviral-mediated PICALM transfer. Inducible pluripotent stem cell–derived human endothelial cells carrying the rs3851179 protective allele exhibited higher PICALM levels and enhanced Aβ clearance. Thus, PICALM regulates Aβ BBB transcytosis and clearance, which has implications for Aβ brain homeostasis and clearance therapy.

20 January 2005 in Nature
Verified
Journal Article
Closed access
TMTakahiro Maeda
Takahiro Maeda
RHRobin M. Hobbs
Robin M. Hobbs
TMTaha Merghoub
Taha Merghoub
IGIlhem Guernah
Ilhem Guernah
AZArthur Zelent
Arthur Zelent
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

15 January 2016 in Science
Verified
Journal Article
Closed access
PDF file
TMTakeshi Masuda
Takeshi Masuda
XWXin Wang
Xin Wang
MMManami Maeda
Manami Maeda
MCMatthew C. Canver
Matthew C. Canver
FSFalak Sher
Falak Sher
TMTakahiro Maeda
Takahiro Maeda
Reactivating the fetal globin gene: Mutation of adult-type globin genes causes sickle cell disease and thalassemia. Although treating these hemoglobinopathies with gene therapy is possible, there is a pressing need for pharmacologic approaches to treat general patient populations. One promising approach is to reactivate repressed expression of fetal-type hemoglobin (HbF) in adult erythroid cells. Masuda et al. reveal a molecular mechanism governing HbF repression as mediated by the LRF/ZBTB7A transcription factor. The study may encourage the development of new HbF reactivation therapies for hemoglobinopathies. Science , this issue p. 285

1 August 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MCMatthew C. Canver
Matthew C. Canver
DBDaniel E. Bauer
Daniel E. Bauer
ADAbhishek Dass
Abhishek Dass
YYYvette Y. Yien
Yvette Y. Yien
JCJacky Chung
Jacky Chung
SOStuart H. Orkin
Stuart H. Orkin
The clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 nuclease system has provided a powerful tool for genome engineering. Double strand breaks may trigger nonhomologous end joining repair, leading to frameshift mutations, or homology-directed repair using an extrachromosomal template. Alternatively, genomic deletions may be produced by a pair of double strand breaks. The efficiency of CRISPR/Cas9-mediated genomic deletions has not been systematically explored. Here, we present a methodology for the production of deletions in mammalian cells, ranging from 1.3 kb to greater than 1 Mb. We observed a high frequency of intended genomic deletions. Nondeleted alleles are nonetheless often edited with inversions or small insertion/deletions produced at CRISPR recognition sites. Deleted alleles also typically include small insertion/deletions at predicted deletion junctions. We retrieved cells with biallelic deletion at a frequency exceeding that of probabilistic expectation. We demonstrate an inverse relationship between deletion frequency and deletion size. This work suggests that CRISPR/Cas9 is a robust system to produce a spectrum of genomic deletions to allow investigation of genes and genetic elements.

1 April 2012 in Cancer Cell
Verified
Journal Article
Closed access
BZBin Zhang
Bin Zhang
YHYin Wei Ho
Yin Wei Ho
QHQin Huang
Qin Huang
TMTakahiro Maeda
Takahiro Maeda
ALAllen Lin
Allen Lin
RBRavi Bhatia
Ravi Bhatia